Please login to bookmark Close

Bayer and Teva have lost their challenge to Indian drug maker Cipla’s extension of its patent for an allergy medication, with IP Australia finding a failure to pay renewal fees on time was due to a genuine error. 

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au